Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01077700 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 214
- Enrollment target
NCT01077700 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 214 participants.
The verdict
NCT01077700, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 214 participants
- Enrollment target
Study Summary
This is an efficacy and safety study evaluating an experimental treatment for cognitive deficits in adults with schizophrenia.
Interventions
- DRUG Placebo
- DRUG ABT-288 Low Dose
- DRUG ABT-288 High Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01077700
The ClinicalTrials.gov registry entry for NCT01077700 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01077700 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01077700 about?
NCT01077700 is a clinical study titled "Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia". This is an efficacy and safety study evaluating an experimental treatment for cognitive deficits in adults with schizophrenia.
What is the current status of trial NCT01077700?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 214 participants. The study started on 2010-03. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01077700?
The interventions under investigation include: Placebo (DRUG), ABT-288 Low Dose (DRUG), ABT-288 High Dose (DRUG).
Who is sponsoring clinical trial NCT01077700?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.